Esophageal cancer
Conditions
Interventions
Sponsors
Affilated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 70 years old; (2) (ECOG) score of tumor cooperation group in the eastern United States (Annex 1) 0-1; (3) radical operation for esophageal carcinoma (R0 operation); (4) the patients had not been treated with anti-angiogenic targeted drugs in the past. (5) the recurrent site had not received neoadjuvant or adjuvant radiotherapy; (6) Local recurrence after operation, which was defined as anastomotic site, lymph node and tumor bed within the horizontal range from cricothyroid membrane to celiac trunk; (7) the number of lesions was less than 3, which was measured by RECIST standard (Response Evaluation Criteria in Solid Tumors, RECIST, Version 1.1); (8) leukocytes >=3.0x10^9 or neutrophils >=1.5x10^9; hemoglobin >=90 g/L; platelet count >=100x10^9; total bilirubin 3 months; (11) have a full understanding of this study, have the ability to complete the treatment, and have the conditions for follow-up to sign the informed consent form voluntarily.
Exclusion criteria
Exclusion criteria: (1) A history of malignant tumors in other parts (previous or simultaneous), excluding curable non-melanomatous skin cancer and cervical carcinoma in situ (survival without disease progression for at least 3 years); (2) patients with distant metastasis; (3) has received anti-angiogenic targeted drug therapy in the past; (4) pregnant and lactating patients; (5) patients with uncontrolled diabetes, hypertension, coronary heart disease and abnormal renal function; (6) there is a tendency of bleeding or perforation, or there is a hemorrhagic disease; (7) the recurrent site was treated with radiotherapy; (8) chemotherapy was received after local recurrence, and the chemotherapy was effective. (9) oral or intravenous administration of hormones at the same time; (10) active infection; (11) hyperarteriovenous thrombosis occurred within 6 months, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis and pulmonary embolism; (12) there are situations in which other researchers believe that this clinical study cannot be completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate and toxicity; | — |
Countries
China
Contacts
Public ContactHong Ge
Affilated Cancer Hospital of Zhengzhou University
Outcome results
None listed